Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsPosterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK VeröffentlichungenAutologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond
/in Dendritic Cells, Hypernephroma, International PublicationsEfficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsAutologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study
/in Dendritic Cells, International Publications, Pancreatic CancerNewcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model
/in Colorectal Cancer, International Publications, Newcastle Disease VirusWilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
/in Acute Leukemia, Dendritic Cells, International PublicationsA comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
/in Dendritic Cells, Glioblastoma, International PublicationsLong-Term Feasibility of 13.56 MHz Modulated Electro-Hyperthermia-Based Preoperative Thermoradiochemotherapy in Locally Advanced Rectal Cancer
/in Colorectal Cancer, Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer